Epidemiology of hepatitis E virus infection in Turkey

David L Thomas, Thomas C Quinn, R. W. Mahley, K. E. Palaoglu, S. Badur

Research output: Contribution to journalArticle

Abstract

The seroprevalence and risk factors for infection with hepatitis E virus (HEV) were analysed in five regions of Turkey, where one-third of acute hepatitis cases are non-A, non-B. Antibodies to HEV (anti-HEV) were found in 80 (5·9%) of 1350 subjects. Independent predictors of anti-HEV were age over 25 years, less than elementary education, antibodies to hepatitis C virus, and residence in the warmest region (Adana). Whereas none of 105 subjects in the second decade of life were HEV seropositive, 17 (3·7%) of 464 and 28 (9·1 %) of 308 of those in the third and fourth decades of life, respectively, had anti-HEV (p

Original languageEnglish (US)
Pages (from-to)1561-1562
Number of pages2
JournalThe Lancet
Volume341
Issue number8860
DOIs
StatePublished - Jun 19 1993

Fingerprint

Hepatitis E virus
Virus Diseases
Turkey
Epidemiology
Antibodies
Hepatitis C Antibodies
Seroepidemiologic Studies
Hepatitis
Education
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Epidemiology of hepatitis E virus infection in Turkey. / Thomas, David L; Quinn, Thomas C; Mahley, R. W.; Palaoglu, K. E.; Badur, S.

In: The Lancet, Vol. 341, No. 8860, 19.06.1993, p. 1561-1562.

Research output: Contribution to journalArticle

Thomas, David L ; Quinn, Thomas C ; Mahley, R. W. ; Palaoglu, K. E. ; Badur, S. / Epidemiology of hepatitis E virus infection in Turkey. In: The Lancet. 1993 ; Vol. 341, No. 8860. pp. 1561-1562.
@article{35bb0dc1c00340b094494112a9155559,
title = "Epidemiology of hepatitis E virus infection in Turkey",
abstract = "The seroprevalence and risk factors for infection with hepatitis E virus (HEV) were analysed in five regions of Turkey, where one-third of acute hepatitis cases are non-A, non-B. Antibodies to HEV (anti-HEV) were found in 80 (5·9{\%}) of 1350 subjects. Independent predictors of anti-HEV were age over 25 years, less than elementary education, antibodies to hepatitis C virus, and residence in the warmest region (Adana). Whereas none of 105 subjects in the second decade of life were HEV seropositive, 17 (3·7{\%}) of 464 and 28 (9·1 {\%}) of 308 of those in the third and fourth decades of life, respectively, had anti-HEV (p",
author = "Thomas, {David L} and Quinn, {Thomas C} and Mahley, {R. W.} and Palaoglu, {K. E.} and S. Badur",
year = "1993",
month = "6",
day = "19",
doi = "10.1016/0140-6736(93)90698-G",
language = "English (US)",
volume = "341",
pages = "1561--1562",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8860",

}

TY - JOUR

T1 - Epidemiology of hepatitis E virus infection in Turkey

AU - Thomas, David L

AU - Quinn, Thomas C

AU - Mahley, R. W.

AU - Palaoglu, K. E.

AU - Badur, S.

PY - 1993/6/19

Y1 - 1993/6/19

N2 - The seroprevalence and risk factors for infection with hepatitis E virus (HEV) were analysed in five regions of Turkey, where one-third of acute hepatitis cases are non-A, non-B. Antibodies to HEV (anti-HEV) were found in 80 (5·9%) of 1350 subjects. Independent predictors of anti-HEV were age over 25 years, less than elementary education, antibodies to hepatitis C virus, and residence in the warmest region (Adana). Whereas none of 105 subjects in the second decade of life were HEV seropositive, 17 (3·7%) of 464 and 28 (9·1 %) of 308 of those in the third and fourth decades of life, respectively, had anti-HEV (p

AB - The seroprevalence and risk factors for infection with hepatitis E virus (HEV) were analysed in five regions of Turkey, where one-third of acute hepatitis cases are non-A, non-B. Antibodies to HEV (anti-HEV) were found in 80 (5·9%) of 1350 subjects. Independent predictors of anti-HEV were age over 25 years, less than elementary education, antibodies to hepatitis C virus, and residence in the warmest region (Adana). Whereas none of 105 subjects in the second decade of life were HEV seropositive, 17 (3·7%) of 464 and 28 (9·1 %) of 308 of those in the third and fourth decades of life, respectively, had anti-HEV (p

UR - http://www.scopus.com/inward/record.url?scp=0027256755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027256755&partnerID=8YFLogxK

U2 - 10.1016/0140-6736(93)90698-G

DO - 10.1016/0140-6736(93)90698-G

M3 - Article

C2 - 8099641

AN - SCOPUS:0027256755

VL - 341

SP - 1561

EP - 1562

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8860

ER -